Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Trinity Biotech's TRIstat HbA1c test:

This article was originally published in Clinica

Executive Summary

Irish diagnostics firm Trinity Biotech has gained US 510k approval of its TRIstat point-of-care HbA1c blood test. The TRIstat platform detects a patient's level of HbA1c, also known as glycated haemoglobin, a measure of their blood sugar control over the previous two to three months. The American Diabetes Association recommends that diabetic patients be tested for HbA1c at least four times a year. The test uses an affinity two-phase optical system, and can give results within minutes, the Dublin-based company claimed. Launch of the TRIstat product is slated for the first quarter of 2008. Trinity has not yet filed for CE-marking in Europe.

You may also be interested in...

Coronavirus Update: UK Calls For COVID-19 Patients To Join Trials

Australia Relaxes Competition Rules To Facilitate Coronavirus Response

Australia’s competition regulator, the ACCC, has granted a conditional dispensation to allow generics industry association the GBMA and brand body Medicines Australia to work together to help address the coronavirus pandemic by sharing information on stock, inventory, manufacturing and the supply chain. However, tender pricing will not be among the subjects discussed.

Interview: Izana Tests GM-CSF Drug For Coronavirus

The UK biotech's CEO tells Scrip that Izana's objective is to treat rapidly deteriorating COVID-19 patients before ICU admission and prior to ventilation.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts